To reach the next value inflection
LicenseRx asset brief
A Broadly Protective Human Antibody for GI Genogroup Noroviruses
Probability of Success
26% · grade B · Medium data confidence
Model PoS 26% (grade B, medium data confidence). Strongest signals: Data maturity, IP position. Biggest drag: Translational evidence.
Data maturity (22%)
64
Preclinical; in vivo data, human data.
IP position (16%)
72
Patent filed/pending -- prosecution ongoing.
Modality feasibility (14%)
66
Biologic/antibody -- solid path but higher CMC burden.
Indication pull (14%)
75
Infectious Disease, Immunology -- active buyer appetite.
Competitive whitespace (12%)
86
Under-served segment; multi-modal differentiation.
Translational evidence (12%)
62
Public evidence mentions: human, in vivo.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →